ASCO19: gastroesophageal cancer patients may benefit from lower doses of chemotherapy

Written by Rachel Jenkins, Future Science Group

A Phase III GO2 randomized trial has compared treatment for 514 older and frail people with advanced gastroesophageal cancer, the findings will be presented at the 2019 ASCO Annual Meeting (31 May – 4 June 2019, IL, USA). “Previous trials of palliative chemotherapy for gastric and esophageal cancer have not included frail or older patients, therefore the benefit of chemotherapy in these groups was unknown,” commented Peter Hall (University of Edinburgh). Hall continued: “We hope our finding helps patients make a more informed choice, between low-dose chemotherapy and no chemotherapy at all, with the knowledge that that low-dose chemotherapy can prove...

To view this content, please register now for access

It's completely free